Description

Vinpocetine Powder

Introduction

Vinpocetine Powder, derived from the alkaloid vincamine found in the periwinkle plant, stands as a notable research compound in neuroscience. Renowned for its potential cognitive benefits, this product is garnering attention for its various applications in memory research, stroke prevention, and potential implications in cancer studies.

Key Characteristics

Vinpocetine is characterized by its neuroprotective properties and its ability to enhance cerebral blood flow. These characteristics make it a focal point in investigations related to cognitive function and neurological health.

Research Applications

Researchers are actively exploring the diverse applications of Vinpocetine Powder, particularly in the field of neuroscience. Its potential to influence memory, protect against stroke, and its interactions with cancer cells make it a subject of interest in various studies.

Research Benefits

Vinpocetine and Memory Loss

Studies have indicated that Vinpocetine may have a positive impact on memory function, potentially offering neuroprotective effects against age-related cognitive decline and memory loss.

Vinpocetine and Stroke

Research suggests that Vinpocetine may play a role in stroke prevention by improving cerebral blood flow, reducing inflammation, and protecting against neuronal damage. Investigations are ongoing to understand its potential in mitigating the effects of stroke.

Vinpocetine and Cancer

Preliminary studies have explored Vinpocetine’s effects on cancer cells, indicating potential anti-cancer properties. Researchers are delving into the mechanisms through which Vinpocetine may influence cancer cell growth and survival.

Summary

Vinpocetine Powder, with its neuroprotective and cognitive-enhancing characteristics, holds promise in various research applications. From addressing memory-related concerns to potential implications in stroke prevention and cancer research, Vinpocetine stands as a multifaceted compound deserving further exploration in the realm of neuroscience.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Chukanova EI. [Efficacy of cavinton in the treatment of patients with chronic blood flow insufficiency. Russian multicenter clinical-epidemiological program “CALIPSO”]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):49-52. Russian. PMID: 21311488. [Read More].
2. Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol. 2009 Sep;219(1):53-7. doi: 10.1016/j.expneurol.2009.04.016. Epub 2009 May 4. PMID: 19409385; PMCID: PMC2728790. [Read More].
3. Huang EW, Xue SJ, Zhang Z, Zhou JG, Guan YY, Tang YB. Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis. 2012 Oct;17(10):1120-30. doi: 10.1007/s10495-012-0743-0. PMID: 22729609. [Read More].